Suchergebnisse - "Rahman, Omar"

PubPharm (11)

1

Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the US FDA adverse event reporting system

enthalten in: Immunotherapy | 2021

von Abdel-Rahman, O.

2

Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations : a meta-analysis

enthalten in: Immunotherapy | 2019

von Abdel-Rahman, O.

3

Immune checkpoint inhibitors and non-small-cell lung cancer management : 2018 update

enthalten in: Immunotherapy | 2019

von Abdel-Rahman, O. | Morris, D.

4

Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers : a systematic review

enthalten in: Immunotherapy | 2018

von Abdel-Rahman, O.

5

Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors : a systematic review

enthalten in: Immunotherapy | 2017

von Abdel-Rahman, O. | Eltobgy, M. | Oweira, H. | +3

6

Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors : a systematic review

enthalten in: Immunotherapy | 2017

von Abdel-Rahman, O.

7

Epigenetic regulation of immune checkpoints : another target for cancer immunotherapy?

enthalten in: Immunotherapy | 2017

von Ali, M. | Matboli, M. | Tarek, M. | +8

8

Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma : a systematic review

enthalten in: Immunotherapy | 2016

von Abdel-Rahman, O.

ErratumIn: Immunotherapy. 2017 Mar;9(4):373. - PMID 28303770

9

PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents : a meta-analysis

enthalten in: Immunotherapy | 2016

von Abdel-Rahman, O.

10

A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors

enthalten in: Immunotherapy | 2016

von Abdel-Rahman, O. | Fouad, M.